Introducing Arthrosamid®
Arthrosamid® is a non-biodegradable injectable polyacrylamide hydrogel (2.5% iPAAG) implant that delivers long-lasting pain relief — improving the quality of life for patients with knee OA.
Canada
Arthrosamid® is a single, minimally invasive, long-lasting knee OA treatment — a non-biodegradable injectable polyacrylamide hydrogel (2.5% iPAAG) implant for intra-articular use.
Arthrosamid® is a first-in-class synovial implant delivered as a single, minimally invasive out-patient procedure performed under local anaesthesia, with ultrasound guidance.
Researched for more than two decades, Arthrosamid® has been proven to maintain a statistically significant reduction in pain in patients with knee OA 5 years after treatment.
A single, minimally invasive, long-lasting knee OA treatment, Arthrosamid® has demonstrated an improvement in quality of life with patients in clinical trials reporting a reduction in pain by Week 4 — and lasting over 5 years.
Intra-articular injectable polyacrylamide hydrogel (2.5% iPAAG) implant in Arthrosamid® is made up of 2.5% cross-linked polyacrylamide and 97.5% water.
Arthrosamid®: injectable polyacrylamide hydrogel (2.5% iPAAG) implant
Undergone
over 20 years
of research and development
Around
1,500,000 syringes of 2.5% iPAAG
have been made for human use
Arthrosamid® remains
safe and effective
for its intended use 5 years after treatment
Biocompatible
permeable to salts and organic molecules the hydrogel is able to integrate with soft tissue
Viscoelastic
cross-linked chains of polymer allow flexible shear
Non-degradable
structural stability of hydrogel provides longevity of action
Delivered with a single injection
Arthrosamid® is injected into the synovial cavity, where it disperses within the synovial fluid. Its distribution follows the natural fluid flow of the joint, which is directed by knee movement.
Arthrosamid® is cleared from the synovial cavity and combines with the synovial membrane
Normal intimal transport mechanisms, which remove particulate material from the synovial cavity, also act on Arthrosamid®.
Through this process, the gel is transported through the synovial intima and into the synovial subintima.
Improved knee joint function
The physical presence of Arthrosamid® within the synovial tissue increases elasticity towards that of healthy tissue. By removing stimuli for the mechanical pathway driving OA progression, this leads to improved joint function and long-lasting pain relief.
Complete integration
Once deposited in the synovial subintima, Arthrosamid® becomes integrated — a process largely complete within 4–6 weeks after injection.
The mature, stable local response to the implanted 2.5% iPAAG is characterised by a fine network of collagen fibrils enmeshed with Arthrosamid®, anchoring it as a permanent implant within the subintimal synovium.
This stable integration, 2.5% Polyacrylamide Hydrogel Synovial tissue which results in increased tissue elasticity, means that patients can experience long-lasting pain relief from knee OA.
Delivered with a single injection
Arthrosamid® is injected into the synovial cavity, where it disperses within the synovial fluid. Its distribution follows the natural fluid flow of the joint, which is directed by knee movement.
Pioneering, proven pain treatment for knee OA. Contact us to use Arthrosamid® 2.5 % iPAAG in your knee osteoarthritis patients today.
